Virtual Library
Start Your Search
Yoonki Hong
Author of
-
+
P1.02 - Biology/Pathology (ID 614)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.02-070 - Identification of Lung Cancer Specific Differentially Methylated Regions Using Genome-Wide DNA Methylation Study (ID 9652)
09:30 - 16:00 | Presenting Author(s): Yoonki Hong
- Abstract
Background:
The development of lung cancer is resulted by the interaction between genetic mutations and dynamic epigenetic alterations, although its mechanisms are not fully understood. Among the epigenetic alterations, DNA methylation is the most studied epigenetic regulatory mechanism. DNA methylation changes may be promising biomarker for early detection and prognosis in lung cancer. We evaluated serial changes of genome wide DNA methylation pattern in blood of lung cancer patients.
Method:
Blood samples were obtained for three consecutive years from 3 patients (2 years before, 1 year before, and after lung cancer detection) and from 3 control subjects without lung cancer. We conducted an epigenome-wide analysis using the MethylationEPIC BeadChip which covers 850,000 cytosine-phosphate-guanine (CpG) site. The methylation value (β), a ratio between methylated probe intensity and total probe intensity, is interpreted as the proportion of methylation and ranges between 0 (unmethylated) and 1 (methylated). Significant differentially methylated regions (DMRs) were identified using p values < 0.05 in correlation test for serial methylation changes and serial increase or decrease of β value above 0.1 for three consecutive years.
Result:
We found significant 3 CpG sites with serial changed β values of differentially methylated regions and 7105 CpG sites with significant correlation for serial methylation changes from control patients without lung cancer. However, there were no significant DMRs met both conditions. In contrast, we found significant 11 CpG sites with serial changed β values of differentially methylated regions and 10562 CpG sites with significant correlation for serial methylations changes from patients with lung cancer. There were two significant DMRs met both conditions, cg21126229 (RNF212), cg27098574 (BCAR1).
Conclusion:
This genome-wide DNA methylation study showed DNA methylations changes that might be implicated in lung cancer development. The DNA methylation changes may be candidate target regions for early detection and prevention in lung cancer. Further investigation of these regions and related genes may lead development of a biomarker for lung cancer.
